Beam Therapeutics (BEAM) Q4 2025 earnings summary

Executive summary

• Announced expansion of the liver-targeted portfolio with BEAM-304, a base editing therapy for PKU, targeting the two most common mutations and aiming to address a majority of PKU patients over time, with IND filing anticipated in 2026.

• Provided updates on the anticipated commercialization of risto-cel for sickle cell disease, supported by a new $500M strategic financing agreement with Sixth Street.

• Highlighted the modular, scalable nature of the base editing platform, enabling efficient development of therapies for multiple genetic diseases.

• Outlined progress in preclinical and IND-enabling activities for BEAM-304, with plans to file an IND in 2026 and initial clinical focus on the R408W mutation.

• Emphasized regulatory engagement and adaptive trial designs to accelerate development for multiple mutations and rare diseases.

Financial highlights

• Ended 2025 with $1.25 billion in cash, equivalents, and marketable securities, up from $850.7 million at year-end 2024.

• Secured up to $500 million in long-term, non-dilutive capital from Sixth Street, with $100 million funded at close and additional tranches tied to milestones.

• R&D expenses were $99.3 million for Q4 2025 and $409.6 million for the full year, compared to $101.4 million and $367.6 million in 2024.

• G&A expenses were $32.3 million for Q4 2025 and $113.8 million for the year, up from $28.7 million and $111.5 million in 2024.

• Net income for Q4 2025 was $244.3 million ($2.37 per basic share), while the full year saw a net loss of $80.0 million ($0.81 per share).

Outlook and guidance

• Expect to submit risto-cel BLA as early as year-end 2026 and provide updated phase I/II data for BEAM-302 in alpha-1 antitrypsin deficiency by end of Q1 2026.

• Plan to file IND for BEAM-304 in 2026 and expand the program to additional PKU mutations.

• Continue advancing BEAM-301, BEAM-103, and in vivo HSC editing programs, with BEAM-103 Phase 1 healthy volunteer trial expected to complete dosing in H1 2026.

• Cash runway expected to fund operations into mid-2029, covering major clinical and commercial milestones.